Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
on 11-26-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
New abbreviation here to become acquainted with (PGx) which is pharmacogenics, and one more move in the direction of personalized medicine by big Pharma as the marketing of blockbuster drugs slowly evolves to a new business model with genomic data input becoming a part of the process to bring new drugs...
Posted to
The Medical Quack .... by Barbara Duck
on 11-06-2008
Filed under: Medically Related, Technology, personalized medicine, Genomics, healthcare, Pharma, Pharmacogenomics, Lilly, Pharmacogenetics
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
on 10-26-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
Recently announced is the project to begin at Scripps in San Diego as related news, coupled with the announcement of the new sequencing service that will be able to offer a complete sequence at a wholesale price may have held a bit of inspiration here for Navigenics to enter the full sequencing market...
Posted to
The Medical Quack .... by Barbara Duck
on 10-16-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, Genomics, Pharma, Biotech, DNA Testing, sequencing services
However, their prescription drug unit faced the same problems as the rest of the Pharma industry. A smart investment in consumer products is helping hold things together for J and J. The consumer product division was purchased from Pfizer in 2006, which was the company purchased by Pfizer...
Posted to
The Medical Quack .... by Barbara Duck
on 10-14-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, personalized medicine, Genomics, Pharma, Pfizer, Phamaceuticals, Consumer Goods, J and J, Warner Lambert
As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
on 10-13-2008
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0
Not only do we see venture capital money here, also some big Pharma names. In a related story, Roche sees diagnostic machines and test kits as crucial to assessing and treating disease in the future and their risk profile has recognition of being one large investor in a growing area of drug research...
Posted to
The Medical Quack .... by Barbara Duck
on 10-03-2008
Filed under: Medically Related, Pharma/FDA News, personalized medicine, Genomics, Pharma, Biotech, R and D, Venture Capitalists